For example, the use of ERK1/2 inhibitors in melanoma cells has shown good efficacy in inhibiting the MAPK pathway and cell proliferation, although with some limitations; clinical studies have further validated their usefulness (e.g., NCT01781429, NCT01875705) [63,64,65]. The gene discussed is MAPK3; the disease is melanoma.